Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Minority Interest (2017 - 2020)

Historic Minority Interest for BeOne Medicines (BEIGF) over the last 4 years, with Q3 2020 value amounting to $9.0 million.

  • BeOne Medicines' Minority Interest fell 4276.29% to $9.0 million in Q3 2020 from the same period last year, while for Sep 2020 it was $9.0 million, marking a year-over-year decrease of 4276.29%. This contributed to the annual value of $16.2 million for FY2019, which is 1180.34% up from last year.
  • According to the latest figures from Q3 2020, BeOne Medicines' Minority Interest is $9.0 million, which was down 4276.29% from $10.2 million recorded in Q2 2020.
  • BeOne Medicines' 5-year Minority Interest high stood at $17.4 million for Q2 2019, and its period low was $9.0 million during Q3 2020.
  • Over the past 4 years, BeOne Medicines' median Minority Interest value was $14.4 million (recorded in 2017), while the average stood at $14.0 million.
  • In the last 5 years, BeOne Medicines' Minority Interest soared by 2906.99% in 2019 and then tumbled by 4276.29% in 2020.
  • Quarter analysis of 4 years shows BeOne Medicines' Minority Interest stood at $14.4 million in 2017, then grew by 0.16% to $14.4 million in 2018, then rose by 11.8% to $16.2 million in 2019, then crashed by 44.15% to $9.0 million in 2020.
  • Its Minority Interest was $9.0 million in Q3 2020, compared to $10.2 million in Q2 2020 and $14.8 million in Q1 2020.